https://www.live-feeds.com/feed/breakthrough-vaccine-for-the-deadliest-skin-cancer-cut-risk-by-almost-halfContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/breakthrough-vaccine-for-the-deadliest-skin-cancer-cut-risk-by-almost-halfhttps://www.live-feeds.com/feed/breakthrough-vaccine-for-the-deadliest-skin-cancer-cut-risk-by-almost-half#u155537Mon, 26 Oct 2026 08:20:09 +0000A personalized mRNA vaccine developed by Merck and Moderna significantly reduces the risk of death or recurrence for patients with melanoma, the deadliest form of skin cancer. Late-stage trial results show the experimental treatment cut the risk of the disease returning or resulting in death by 42 percent. The therapeutic approach targets the recurrence of tumors in melanoma patients, offering a promising new direction in skin cancer therapy. While the data signals a major medical advancement, the release of detailed trial statistics on social media also triggered a drop in Moderna shares.Why